Sign in
Taking people in United StatesPhase 4

Tests ertugliflozin with high and low salt diets in type 2 diabetes

Tests ertugliflozin and a low or high salt diet in adults with type 2 diabetes.

Key facts

Who runs it
Amsterdam UMC, location VUmc
Where
Denver, United StatesSee the siteAlso in 1 other country, 1 site
Registry title
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes
Status
Recruiting
Phase
Phase 4
People taking part
34 people, planned
Started
25 Jul 2023
Planned end
Dec 2025
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • ertugliflozine
  • low salt diet
  • placebo
  • high salt diet
Record updated
21 May 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes who are overweight or obese and have mildly reduced kidney function. Women must be past menopause.

Age
18 to 85 years
Sex
Men and women; women must be post-menopausal (no period for more than 1 year).
Disease stage
Type 2 diabetes with HbA1c 6.5-10% (48–86 mmol/mol), BMI above 25 kg/m2, eGFR 60-90 ml/min/1.73m2, UACR below 30 mg/mmol, sodium intake below 200 mmol/day.
Earlier treatment
Must be on a stable dose of diabetes medicine (metformin, SU, DPP4-inhibitors or insulin). People with high blood pressure must be on a stable dose of RAS inhibitors or other blood pressure treatment. SGLT2 inhibitors, TZD, GLP-1RA, glucocorticoids, immune suppressants, antimicrobial agents and chemotherapeutics are not allowed.

Main reasons for not taking part

  • eGFR below 60 or above 90, or UACR above 30 mg/mmol
  • Diabetic ketoacidosis needing medical care within 1 month before screening
  • Heart disease, heart failure or stroke in the last 6 months
  • Severe liver problems or active cancer
  • Current urinary tract infection, active nephritis, or chronic NSAID use

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Adults with previously diagnosed T2DM according to American Diabetes Association (ADA) criteria
  • HbA1c 6.5-10%
  • Age 18 - 85 years of age
  • Overweight or obese with BMI: >25 kg/m2
  • We will make every effort to enrol participants of all races/ethnicities."
  • Both sexes (females must be post-menopausal; no menses >1 year; in case of doubt, Follicle-Stimulating Hormone (FSH) will be determined with cut-off defined as >31 U/L)
  • Ability to provide signed and dated, written informed consent prior to any study procedures
  • Estimated GFR 60-90 ml/min/1.73m2 by CKD-EPI matching the eGFR range of most participants in VERTIS-CV
  • Sodium intake at baseline < 200 mmol/day
  • UACR < 30 mg/mmol
  • All participants need to be on a stable dose of diabetes medication, including Metformin, SU, DPP4-inhibitors, or insulin
  • Participants suffering from hypertension need to be on a stable dose of RAS inhibitors. In case RAS inhibition is not tolerated, the participant should to be on a stable dose of other antihypertensive treatment

Who cannot take part

  • History of diabetic ketoacidosis (DKA) requiring medical intervention (e.g. emergency room visit and/or hospitalization) within 1 month prior to the Screening visit
  • Current urinary tract infection and active nephritis
  • Recent (<6 months) history of cardiovascular disease, including:; Acute coronary syndrome; Chronic heart failure (New York Heart Association grade II-IV); Stroke or transient ischemic neurologic disorder
  • Active malignancy. History of malignancy is allowed unless the participant still has active treatment other than hormonal therapy.• History of or actual severe mental disease
  • Allergy to any of the agents used in the study
  • History of unstable or rapidly progressing renal disease NL80772.029.22 / DC2022ERTU DESIGN Protocol DESIGN, Study NO. 2022.0737 Version 5.0dd22-02-2024 14 of 45; Estimated GFR <60 mL/min/1.73m2 or eGFR > 90 mL/min/1.73m2 determined by CKD-EPI; UACR > 30 mg/mmol; Current/chronic use of the following medication: SGLT2 inhibitors, TZD, GLP-1RA, glucocorticoids, immune suppressants, antimicrobial agents, chemotherapeutics Participants should be on a stable dose of antipsychotics, tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). Subjects on diuretics will only be excluded when these drugs cannot be stopped for the duration of the study; Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) will not be allowed, unless used as incidental medication (1-2 tablets) for non-chronic indications (i.e; sports injury, headache or back ache). However, no such drug can be taken within a timeframe of 2 weeks prior to renal testing
  • Severe hepatic insufficiency and/or significant abnormal liver function defined as aspartate aminotransferase (AST) >3x upper limit of normal (ULN) and/or alanine aminotransferase (ALT) >3x ULN
  • Substance abuse (alcohol: defined as >4 units/day)
  • Individuals who are investigator site personnel, directly affiliated with the study, or are immediate (spouse, parent, child, or sibling, whether biological or legally adopted) family of investigator site personnel directly affiliated with the study
  • Inability to understand the study protocol or give informed consent

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 85 years old?

Where in United States

Also in 1 other country, 1 site

  • Childrens hospital coloradoDenver, United StatesContact: Jessica Kendrick, Prof.Taking people

About the trial

What the trial wants to find out

SGLT2 inhibitors have demonstrated to mitigate cardiorenal risk in people with type 2 diabetes and are likely to play an increasingly large role in the treatment of patients with diabetes, chronic kidney disease and hypertension. Yet the underlying mechanisms of its protective effects are incompletely understood and the salutary effect may be altered by dietary factors such as sodium intake. Therefore, carefully designed mechanistic trials are needed to better understand the interplay between ertugliflozin and salt intake and to potentially modify salt intake to maximize treatment response. In addition, the study could contribute to hypotheses concerning the effects of SGLT2 inhibitors in combination with other drugs that affect sodium homeostasis and could help to explain the differences in kidney outcomes observed in (outcome) trials, which include different ethnicities with potential differences in dietary habits.

The 4 groups in the trial

  • Low salt diet with SGLT2iExisting treatment, for comparison

    10 days of SGLT2i treatment during 20 days of low salt diet

    Treatment: ertugliflozine and low salt diet

  • Low salt diet with placeboPlacebo, for comparison

    10 days of placebo during 20 days of low salt diet

    Treatment: low salt diet and placebo

  • High salt diet with SGLT2iExisting treatment, for comparison

    10 days of SGTL2i during 20 days of high salt diet.

    Treatment: ertugliflozine and high salt diet

  • High salt diet with placeboPlacebo, for comparison

    10 days of placebo during 20 days of high salt diet.

    Treatment: placebo and high salt diet

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes
Plain-language title
Tests ertugliflozin with high and low salt diets in type 2 diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06983054, who can take part
Record updated
21 May 2025